Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial.
Fangfang SunWenyan HuangJie ChenLiling ZhaoDanting ZhangXiaodong WangWeiguo WanSheng-Ming DaiSheng ChenTing LiShuang YePublished in: Lupus science & medicine (2022)
NCT04515719.
Keyphrases
- double blind
- disease activity
- systemic lupus erythematosus
- placebo controlled
- low dose
- clinical trial
- rheumatoid arthritis patients
- phase ii
- ankylosing spondylitis
- study protocol
- randomized controlled trial
- phase iii
- high dose
- juvenile idiopathic arthritis
- phase ii study
- rheumatoid arthritis
- open label
- squamous cell carcinoma
- rectal cancer